On August 5, Astera Labs, Inc. declined 4.15% in regular trading, trading at $335.28/share, with turnover of $265 million. The stock had surged over 11% earlier in the session before sharply reversing course.

On the news front, despite reporting stellar Q2 results — adjusted EPS of $0.80 versus the $0.69 consensus estimate and revenue of $392.4 million versus the $360.7 million estimate — and issuing Q3 revenue guidance of $540-560 million far exceeding the $417 million market consensus, the stock experienced significant intraday profit-taking. RBC Capital raised its price target from $425 to $500 maintaining an Outperform rating, while Morgan Stanley had previously lifted its target to $335 from $240. The sharp reversal reflected concentrated selling by investors capitalizing on substantial accumulated gains from the prior rally. Additionally, divergence within the semiconductor sector weighed on high-beta names, with Advanced Micro Devices down 5.63% and Intel down 1.32%, creating broader headwinds for momentum stocks in the space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)